Stock & Company Details
BioXcel Therapeutics Inc $BTAI
Price:
N/A
N/A
31M
$23M
52 Week High:
N/A
10 Day Average Volume:
N/A
-0.03
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
BTAI technical indicators
Latest BioXcel Therapeutics Inc (BTAI) indicator readings as of 2026-08-28.
BTAI's 14-day RSI is 21.8, in oversold territory. At $0.18 it is trading 86.8% below its 200-day moving average of $1.38, and below its 50-day average of $0.95. Price sits below the lower Bollinger Band ($0.45 to $1.23). ADX reads 15.4, indicating a range-bound market rather than a trend.
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Finance Bot
Ask your questions
Start by typing a question below.
